Stock listing

Lang & Schwarz:529882 Corcept Therapeutics Incorporated Aktie

German listing (Lang & Schwarz) of Corcept Therapeutics Incorporated · home listing NASDAQ:CORT

Follow Corcept Therapeutics Incorporated into a list and get an email when it puts out news.

Home listing price · NASDAQ:CORT

$110.16 USD -3.21 (-2.8%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CORT

Since Jul 6, 2026 +20.2% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$107.79 – $113.64 USDOct 16, 2026
Volume
849,640 sharesOct 16, 2026
Market value
$11.91B USDAt the close on Oct 16, 2026 · price × 108.1M shares outstanding
Corcept Therapeutics Incorporated logo
Ticker
Lang & Schwarz:529882
Asset type
Stock
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • Corcept Therapeutics (NASDAQ:CORT) Q2 2026 Earnings Call

    Wed, Jul 29, 2026 · 5:00 PM ET

    Watch Transcript

  • Corcept Therapeutics (NASDAQ:CORT) Q1 2026 Earnings Call

    Thu, Apr 30, 2026 · 5:00 PM ET

    Watch Transcript

  • Corcept Therapeutics (NASDAQ:CORT) Q4 2025 Earnings Call

    Tue, Feb 24, 2026 · 5:00 PM ET

    Watch Transcript

Latest news

Corcept Announces Planned Leadership Transition

Sep 23, 2026

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Sep 18, 2026

Corton Capital Inc. Announces Launch of Corton Rosenberg Global Macro Fund

Sep 9, 2026

CORRECTION FROM SOURCE: Corton Capital Inc. Announces August 2026 Distributions for the Exchange Traded Fund

Aug 25, 2026

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Jun 17, 2026

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

Jun 6, 2026

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

May 29, 2026

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Apr 30, 2026

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Apr 21, 2026

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Apr 10, 2026

All Corcept Therapeutics Incorporated news

Decks

Corcept Therapeutics Incorporated on 6ix

News releases
23 in the last 12 months · 131 in all · newest Sep 23, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Jul 29, 2026
Decks
6 decks · latest Apr 10, 2026

Where Corcept Therapeutics Incorporated is listed

ListingExchangeCountryCurrency
NASDAQ:CORT · Home listingNASDAQUnited StatesUSD
gettex:HTDgettexGermanyEUR
LS Exchange:529882LS ExchangeGermanyEUR
Lang & Schwarz:529882 · This pageLang & SchwarzGermanyEUR
BOATS:CORTBOATSUnited StatesUSD
Tradegate:HTDTradegateGermanyEUR
Milan:1CORTMilanItalyEUR
LSE:0I3QLSEUnited KingdomUSD
Frankfurt:HTDFrankfurtGermanyEUR
BX Swiss:HTDBX SwissSwitzerlandCHF
Dusseldorf:HTDDusseldorfGermanyEUR
Hamburg:HTDHamburgGermanyEUR
Munich:HTDMunichGermanyEUR
Stuttgart:HTDStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Corcept Therapeutics Incorporated.